For more than 20 years, the dopamine hypothesis has been the dominating hypothesis for the pathophysiology of schizophrenia. It states that the symptoms of schizophrenia are related to increased central dopaminergic transmission. The hypothesis was supported when increased densitites of D2-dopamine receptors were demonstrated in post-mortem brains from patients with schizophrenia. Increased densities, however, may have been caused by neuroleptic drug treatment during life-time. Using positron emission Tomography (PET) and 11C- labelled radioligands it is possible to test the hypothesis in young never neuroleptic-treated patients with schizophrenia. One research group used a kinetic model and the radioligand 11C-NMSP and found a two- to three-fold elevation in D2-dopamine receptor densities in young drug-naive schizophrenic patients. The present applicant used 11C- raclopride and an equilibrium model and found no difference. For future schizophrenia research it is of key interest to resolve this discrepancy. The first specific aim of the present continuation project is to compare the two quantitative methods in the same individuals and to replicate the study with 11C-NMSP in Swedish drug-naive schizophrenic subjects.
A second aim i s to examine if longterm neuroleptic drug treatment causes an increase in the density of central D2-dopamine receptors in man. Using PET it has been demonstrated that clinical doses of neuroleptics representing all the chemical classes used today, block-D2-dopamine receptors to a high degree. The individual response to neuroleptic drug treatment is highly variable and in some patients severe side effects are recorded. In order to reduce the risk of side effects the titration of the minimal antipsychotic dose in each patient is a necessity. There is need for useful measures to guide the dose-finding procedure.
A specific aim of the present project is to relate D2-dopamine receptor occupancy for the classical antipsychotic haloperidol and for the atypical antipsychotic clozapine to antipsychotic effect and to extrapyramidal side effect. It may be possible to define a dose-response relationship or a """"""""threshold occupancy"""""""" for the antipsychotic effect. In this way a principally new measure could be obtained to guide the clinical selection of optimal doses for antipsychotic drug treatment. Additional aims of the application is to study D2-receptor occupancy during treatment with depot neuroleptics and with very high doses of neuroleptics.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project (R01)
Project #
5R01MH041205-07
Application #
3379734
Study Section
Psychopathology and Clinical Biology Research Review Committee (PCB)
Project Start
1986-05-01
Project End
1994-08-31
Budget Start
1992-09-30
Budget End
1993-08-31
Support Year
7
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Karolinska Institute
Department
Type
DUNS #
350582235
City
Stockholm
State
Country
Sweden
Zip Code
171 7-7
Talvik, Mirjam; Nordstrom, Anna-Lena; Okubo, Yoshiro et al. (2006) Dopamine D2 receptor binding in drug-naive patients with schizophrenia examined with raclopride-C11 and positron emission tomography. Psychiatry Res 148:165-73
Pike, Victor W; Halldin, Christer; Nobuhara, Kenji et al. (2003) Radioiodinated SB 207710 as a radioligand in vivo: imaging of brain 5-HT4 receptors with SPET. Eur J Nucl Med Mol Imaging 30:1520-8
Andree, Bengt; Halldin, Christer; Pike, Victor W et al. (2002) The PET radioligand [carbonyl-(11)C]desmethyl-WAY-100635 binds to 5-HT(1A) receptors and provides a higher radioactive signal than [carbonyl-(11)C]WAY-100635 in the human brain. J Nucl Med 43:292-303
Olsson, H; Farde, L (2001) Potentials and pitfalls using high affinity radioligands in PET and SPET determinations on regional drug induced D2 receptor occupancy--a simulation study based on experimental data. Neuroimage 14:936-45
Bergstrom, K A; Halldin, C; Savonen, A et al. (1999) Iodine-123 labelled Z-(R,R)-IQNP: a potential radioligand for visualization of M(1 )and M(2) muscarinic acetylcholine receptors in Alzheimer's disease. Eur J Nucl Med 26:1482-5
Ito, H; Halldin, C; Farde, L (1999) Localization of 5-HT1A receptors in the living human brain using [carbonyl-11C]WAY-100635: PET with anatomic standardization technique. J Nucl Med 40:102-9
Chou, Y H; Karlsson, P; Halldin, C et al. (1999) A PET study of D(1)-like dopamine receptor ligand binding during altered endogenous dopamine levels in the primate brain. Psychopharmacology (Berl) 146:220-7
Nyberg, S; Eriksson, B; Oxenstierna, G et al. (1999) Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. Am J Psychiatry 156:869-75
Ito, H; Okubo, Y; Halldin, C et al. (1999) Mapping of central D2 dopamine receptors in man using [11C]raclopride: PET with anatomic standardization technique. Neuroimage 9:235-42
Sandell, J; Halldin, C; Hall, H et al. (1999) Radiosynthesis and autoradiographic evaluation of [11C]NAD-299, a radioligand for visualization of the 5-HT1A receptor. Nucl Med Biol 26:159-64

Showing the most recent 10 out of 71 publications